about
sameAs
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant gliomaAn integrated genomic analysis of human glioblastoma multiformeIDH1 and IDH2 mutations in gliomasIn Tribute to Mike Traynor (1939-2009)Toxin-based targeted therapy for malignant brain tumorsAntibody, T-cell and dendritic cell immunotherapy for malignant brain tumorsAberrant Otx2 expression enhances migration and induces ectopic proliferation of hindbrain neuronal progenitor cellsA phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.Glioma stem cells promote radioresistance by preferential activation of the DNA damage responseMutations of the BRAF gene in human cancerDeletion-mutant epidermal growth factor receptor in human gliomas: effects of type II mutation on receptor functionTransforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell linesDeletion of p16 and p15 genes in brain tumorsMutations in CIC and FUBP1 contribute to human oligodendrogliomaSubgroup-specific structural variation across 1,000 medulloblastoma genomesProtein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapyThe somatic genomic landscape of glioblastomaIdentification of an amplified, highly expressed gene in a human gliomaThe genetic landscape of the childhood cancer medulloblastomaGlycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiformeIdentification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acidChemotherapy of subcutaneous and intracranial human medulloblastoma xenografts in athymic nude miceA pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastomaA novel method for volumetric MRI response assessment of enhancing brain tumorsStem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factorSomatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types.Kinetics and glial fibrillary acidic (GFA) protein production in a transplantable human giant cell glioblastoma (D-212 MG) of near haploid karyotype maintained in an organ culture system. An immunohistochemistry study.Relationship of the demonstration of intermediate filament protein to kinetics of three human neuroepithelial tumor cell lines. Lack of neural-related proteins in most cells in S phase: a double-labeled immunohistochemical study on matrix cultures.Characterization of cDNA encoding mouse DNA repair protein O6-methylguanine-DNA methyltransferase and high-level expression of the wild-type and mutant proteins in Escherichia coli.Monoclonal antibody therapy of human gliomas: current status and future approaches.MRP3: a molecular target for human glioblastoma multiforme immunotherapy.Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma.Phase II trial of temozolomide in patients with progressive low-grade glioma.Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiformeA pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost.Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma.Identification of microbial DNA in human cancer.Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy.Treatment of patients with pineoblastoma with high dose cyclophosphamide.
P50
Q24644727-FB5560CD-0BE5-4B0A-B881-8E28552ABF48Q24648860-E56781BF-4130-4391-876C-3BBEB153B8B0Q24648948-8BC892AD-5855-4A2D-BEB9-69267C56B5F9Q24650520-4648E02B-D55E-43D5-8E49-40FF2B19FC8CQ27006226-50787E86-985D-4CB6-B0A3-C7C4945747BBQ27011298-C817743E-C9C9-4626-A89E-5A2D81FF1C13Q27303725-F755DD0D-3876-447A-B3BD-BE20683FF443Q27853118-5067F7A8-A1D2-4185-90A6-2865F27C7ACDQ27860541-B206297F-26A7-43D9-B18A-5C0246D69CA0Q27860760-F0F0724B-976A-4CBC-AF90-9EF1E229A816Q28119050-FFF58AF3-7270-43DB-AC84-EC82ED99C1A8Q28138728-E25118ED-D69A-4C0C-92F1-54DD9AD2FA11Q28242452-EC79F6E5-9A79-4337-8E0C-4A2609163F04Q28244895-BD44A97C-C9B1-4870-9891-2E94049C917CQ28271811-F260146B-5A65-480F-A19E-C6DCA2E61518Q28279046-A69F8542-E6F0-448E-95FE-6BCBC96BB5FCQ28300185-B35C4DF0-9118-4CEF-82B6-80C41F8E6061Q28300727-24BE5CC6-E2D5-4D94-8646-E6F84A861649Q28301196-F86A21BC-D393-4B05-936D-5A6C1F72EEA2Q28306737-D0B022C0-4F9A-4C63-A327-17DB841474DDQ28307014-4C5A6C6C-2D63-45D0-8E8D-C05D6D7FB717Q28336487-9CF9AE1E-7407-415E-9DA7-EB7A7BA69CCFQ28731711-BD71943F-37FA-4033-940C-F1428BEF0D64Q28743259-0ABB54BE-192F-4D15-9847-3B9B2411C7A7Q29617062-20FD05C0-C4E7-4094-9AC9-D793C12F2AF6Q30423124-367386F8-C224-41C6-8918-01D4E2D7CFE0Q30456294-89FA3DB3-8D34-47B8-BB1C-F74F30831080Q30458702-FE047537-3BED-4244-A713-7BB922A25705Q30736503-04BC3732-8817-48CB-85B9-20020962E018Q30879745-DDFC8C09-B220-4ED5-8F2D-9716ABD54B79Q30988770-0279974D-9ACD-4004-8C93-893C34D4B645Q33334642-A0E5D863-F47F-451F-92A6-FD07B62E56C6Q33346531-771F8CB6-52A6-451A-A2A6-170CAD45D4F7Q33370229-62BF2CA8-CDE1-4531-B139-31B93025778FQ33373293-4C942457-53E6-4C20-B083-4921EE0FB133Q33378699-D22FEAF2-080A-4CAD-A868-931631837AB1Q33383721-62808CEC-21C2-48FA-A7D4-74066DED680BQ33441903-3A2D9AC7-C362-47BC-B0BB-5814CC4D3A5AQ33465104-3FBA78C8-EA93-4715-B0A3-841C9CFD14F9Q33495572-DF884196-E674-42C5-9678-4181538AEA9D
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Darell D Bigner
@ast
Darell D Bigner
@es
Darell D Bigner
@nl
Darell D. Bigner
@en
type
label
Darell D Bigner
@ast
Darell D Bigner
@es
Darell D Bigner
@nl
Darell D. Bigner
@en
altLabel
Bigner D
@en
Bigner D. D.
@en
Bigner D.
@en
Bigner DD
@en
Bigner
@en
D Bigner
@en
D D Bigner
@en
D. Bigner
@en
D. D. Bigner
@en
Darell Bigner
@en
prefLabel
Darell D Bigner
@ast
Darell D Bigner
@es
Darell D Bigner
@nl
Darell D. Bigner
@en
P101
P106
P108
P21
P31
P496
0000-0001-5548-4899